Close Menu
Home » Rosetta Genomics to Restructure, Cut 20 Percent of Workforce

Rosetta Genomics to Restructure, Cut 20 Percent of Workforce

Oct 05, 2010

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rosetta Genomics today announced that it will undertake a restructuring that is expected to reduce the company's monthly burn rate 32 percent.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

And Out

A genetic genealogy analysis helped secure the release of a California man from prison after getting his murder conviction overturned, the Guardian reports.

Quick Generation

Technology Review discusses the concerns that come along with the ability to quickly synthesize viruses like SARS-CoV-2.

Phages With More

Researchers have uncovered large bacteriophages whose genomes include translational machinery, Live Science reports.

PNAS Papers Examine Prostate Cancer Splicing, Arabidopsis Methylation, X Chromosome Dosage Effects

In PNAS this week: role for Myc in alternative splicing regulation in prostate cancer, variation in methylation in Arabidopsis, and more.

Feb
20
Featured Webinar

Advances in NGS Gene Expression Studies to Reduce The Cost of Sequencing

Sponsored by
Thermo Fisher Scientific

This webinar will discuss the use of 3’ mRNA sequencing to reduce the cost of gene expression studies on Illumina NGS systems.

Mar
18
Featured Webinar

Comparison of Genome-Wide versus Targeted cfDNA Testing for First-Line Prenatal Screening: Real-World Data

Sponsored by
Roche

This webinar will discuss data from a recent real-world comparison study evaluating performance of two cell-free DNA methodologies as first-line prenatal screens.

Mar
31
Featured Webinar

The Role of Single-Cell Functional Biomarkers in Next-Generation Cancer Therapies

Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.

What's Popular?

In Diagnostics

  1. Amid Customer Complaints, Genetic Testing Firm Pathway OME Acquired by OME Wellness

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.